XML 65 R31.htm IDEA: XBRL DOCUMENT
v3.19.2

Intangible Assets (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2019
Intangible Assets, Net (Excluding Goodwill) [Abstract] |
Schedule of Finite-Lived Intangible Assets | The following table summarizes our intangible assets, net (in millions):
|  | June 30, 2019 |  | December 31, 2018
|  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset - sofosbuvir |  | $ | 10,720 |  |  | $ | (3,903 | ) |  | $ | — |  |  | $ | 6,817 |  |  | $ | 10,720 |  |  | $ | (3,554 | ) |  | $ | — |  |  | $ | 7,166 |
Intangible asset - axicabtagene ciloleucel (DLBCL) |  | 6,200 |  |  | (588 | ) |  | — |  |  | 5,612 |  |  | 6,200 |  |  | (416 | ) |  | — |  |  | 5,784 |
Intangible asset - Ranexa |  | 688 |  |  | (688 | ) |  | — |  |  | — |  |  | 688 |  |  | (678 | ) |  | — |  |  | 10 |
Other |  | 1,098 |  |  | (415 | ) |  | (3 | ) |  | 680 |  |  | 1,096 |  |  | (359 | ) |  | (3 | ) |  | 734 |
Total finite-lived assets |  | 18,706 |  |  | (5,594 | ) |  | (3 | ) |  | 13,109 |  |  | 18,704 |  |  | (5,007 | ) |  | (3 | ) |  | 13,694 |
Indefinite-lived assets - In Process Research & Development |  | 2,047 |  |  | — |  |  | (4 | ) |  | 2,043 |  |  | 2,047 |  |  | — |  |  | (3 | ) |  | 2,044 |
Total intangible assets |  | $ | 20,753 |  |  | $ | (5,594 | ) |  | $ | (7 | ) |  | $ | 15,152 |  |  | $ | 20,751 |  |  | $ | (5,007 | ) |  | $ | (6 | ) |  | $ | 15,738 |
Schedule of Indefinite-Lived Intangible Assets | The following table summarizes our intangible assets, net (in millions):
|  | June 30, 2019 |  | December 31, 2018
|  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset - sofosbuvir |  | $ | 10,720 |  |  | $ | (3,903 | ) |  | $ | — |  |  | $ | 6,817 |  |  | $ | 10,720 |  |  | $ | (3,554 | ) |  | $ | — |  |  | $ | 7,166 |
Intangible asset - axicabtagene ciloleucel (DLBCL) |  | 6,200 |  |  | (588 | ) |  | — |  |  | 5,612 |  |  | 6,200 |  |  | (416 | ) |  | — |  |  | 5,784 |
Intangible asset - Ranexa |  | 688 |  |  | (688 | ) |  | — |  |  | — |  |  | 688 |  |  | (678 | ) |  | — |  |  | 10 |
Other |  | 1,098 |  |  | (415 | ) |  | (3 | ) |  | 680 |  |  | 1,096 |  |  | (359 | ) |  | (3 | ) |  | 734 |
Total finite-lived assets |  | 18,706 |  |  | (5,594 | ) |  | (3 | ) |  | 13,109 |  |  | 18,704 |  |  | (5,007 | ) |  | (3 | ) |  | 13,694 |
Indefinite-lived assets - In Process Research & Development |  | 2,047 |  |  | — |  |  | (4 | ) |  | 2,043 |  |  | 2,047 |  |  | — |  |  | (3 | ) |  | 2,044 |
Total intangible assets |  | $ | 20,753 |  |  | $ | (5,594 | ) |  | $ | (7 | ) |  | $ | 15,152 |  |  | $ | 20,751 |  |  | $ | (5,007 | ) |  | $ | (6 | ) |  | $ | 15,738 |
Schedule of Estimated Future Amortization Expense | The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of June 30, 2019 (in millions):
Fiscal Year |  | Amount
2019 (remaining six months) |  | $ | 563 |
2020 |  | 1,125 |
2021 |  | 1,125 |
2022 |  | 1,125 |
2023 |  | 1,125 |
Thereafter |  | 8,046 |
Total |  | $ | 13,109 |

X
- References No definition available. + Details
Name: | us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b),(d) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration